Effects of Tirofiban combined with low molecular weight heparin in treatment of patients with acute myocardial infarction undergoing percutaneous coronary intervention
Objective:To observe effects of Tirofiban combined with low molecular weight heparin in treatment of patients with acute myocardial infarction undergoing percutaneous coronary intervention(PCI).Methods:A prospective study was conducted on 100 patients with acute myocardial infarction admitted to this in hospital from November 2022 to November 2023.They were divided into study group and control group according to the random number table method,50 cases each.Both groups were treated with PCI.On this basis,the control group was treated with low molecular weight heparin,while the study group was treated with Tirofiban on the basis of that of the control group.The clinical efficacy,the cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)]levels,the myocardial injury markers[creatine kinase isoenzyme(CK-MB),cardiac troponin I(cTnI),N-terminal pro-brain natriuretic peptide(NT-proBNP)]levels,the incidence of major cardiovascular adverse events,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 96.00%(48/50),which was higher than 84.00%(42/50)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the level of LVEF in the study group was higher than that in the control group,the levels of LVESD and LVEDD were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of cTnI,CK-MB and NT-proBNP in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of major adverse cardiovascular events in the study group was 4.00%(2/50),which was lower than 14.00%(9/50)in the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Low molecular weight heparin combined with Tirofiban in the treatment of the patients with acute myocardial infarction undergoing PCI can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of myocardial injury markers and the incidence of major cardiovascular adverse events.Moreover,it is superior to simple Tirofiban treatment.
万方数据
维普
